DISC-3405 cuts phlebotomy events 85% in PV Phase 2; hematocrit controlled <45%

Disc Medicine, Inc.

Mean phlebotomy events fell from 4.0 to 0.6 per 26 weeks (p<0.0001) in Cohort A (n=13).
61.5% of patients phlebotomy-free through 26 weeks; 77.8% during maintenance (weeks 12-32, n=9).
Hematocrit maintained <45% through week 26 with improved symptom burden; dose-proportional PK, increased hepcidin.
DISC-3405 well-tolerated; mild injection site reactions; adverse events consistent with underlying disease.
Company plans RESTORE-PV update and sickle cell data by end of 2026; selcodebart FDA feedback expected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.